USA Pancreas Graft Outcomes by Induction Therapy

Pancreas GSRs in 1996-2002 US cadaver primary pancreas transplant recipients who were given Tac+MMF for maintenance therapy were analyzed according to antibody induction used: none; depleting antibody; non-depleting antibody; depleting+non-depleting antibodies. These induction therapy analyses were done for each of the major recipient groups: SPK, PAK, PTA.

SPK Outcome by Induction Therapy

For SPK MMF+Tac recipients, 1-year GSRs were highest for non-depleting antibodies, but differences were small: 83%-87% (Figure 16). For BD recipients there were no significant GSR differences by induction therapy, but for ED recipients the differences were significant even though small (p=0.02): GSR range at two years 80% for no antibodies to 86% for non-depleting antibodies.

Figure 16

PAK Outcome by Induction Therapy

For PAK MMF+Tac recipients, there was no significant difference by induction therapy protocol in overall pancreas GSRs at one-year: 79%-81% (Figure 17a). This was also true for the BD subset, but for the ED subset 1-year GSRs were highest at 81% using non-depleting antibodies (p=0.12). PAK has the largest retransplant group; GSRs were not statistically different by induction therapy, but tended to be higher with the use of antibodies for induction vs. no induction antibodies (Figure 17b).

Figure 17a

Figure 17b

Figure 18